Search

Your search keyword '"Agblewonu, K.B. (Koffi)"' showing total 2 results
Start Over Author "Agblewonu, K.B. (Koffi)"
2 results on '"Agblewonu, K.B. (Koffi)"'

1. African Programme for Onchocerciasis Control 1995-2015: Updated Health Impact Estimates Based on New Disability Weights

Author

Coffeng, L.E. (Luc), Stolk, W.A. (Wilma), Zouré, H.G.M. (Honorat G.), Veerman, J.L. (Lennert), Agblewonu, K.B. (Koffi), Murdoch, M.E. (Michele), Noma, M. (Mounkaila), Fobi, G. (Grace), Richardus, J.H. (Jan Hendrik), Bundy, D.A.P. (Donald A.), Habbema, J.D.F. (Dik), Vlas, S.J. (Sake) de, Amazigo, U.V. (Uche), Coffeng, L.E. (Luc), Stolk, W.A. (Wilma), Zouré, H.G.M. (Honorat G.), Veerman, J.L. (Lennert), Agblewonu, K.B. (Koffi), Murdoch, M.E. (Michele), Noma, M. (Mounkaila), Fobi, G. (Grace), Richardus, J.H. (Jan Hendrik), Bundy, D.A.P. (Donald A.), Habbema, J.D.F. (Dik), Vlas, S.J. (Sake) de, and Amazigo, U.V. (Uche)

Published
2014
Full Text
View/download PDF

2. African Programme for Onchocerciasis Control 1995-2015: Model-Estimated Health Impact and Cost

Author

Coffeng, L.E. (Luc), Stolk, W.A. (Wilma), Zouré, H.G.M. (Honorat G.), Veerman, J.L. (Lennert), Agblewonu, K.B. (Koffi), Murdoch, M.E. (Michele), Noma, M. (Mounkaila), Fobi, G. (Grace), Richardus, J.H. (Jan Hendrik), Bundy, D.A.P. (Donald A.), Habbema, J.D.F. (Dik), Vlas, S.J. (Sake) de, Amazigo, U.V. (Uche), Coffeng, L.E. (Luc), Stolk, W.A. (Wilma), Zouré, H.G.M. (Honorat G.), Veerman, J.L. (Lennert), Agblewonu, K.B. (Koffi), Murdoch, M.E. (Michele), Noma, M. (Mounkaila), Fobi, G. (Grace), Richardus, J.H. (Jan Hendrik), Bundy, D.A.P. (Donald A.), Habbema, J.D.F. (Dik), Vlas, S.J. (Sake) de, and Amazigo, U.V. (Uche)

Abstract

Background: Onchocerciasis causes a considerable disease burden in Africa, mainly through skin and eye disease. Since 1995, the African Programme for Onchocerciasis Control (APOC) has coordinated annual mass treatment with ivermectin in 16 countries. In this study, we estimate the health impact of APOC and the associated costs from a program perspective up to 2010 and provide expected trends up to 2015. Methods and Findings: With data on pre-control prevalence of infection and population coverage of mass treatment, we simulated trends in infection, blindness, visual impairment, and severe itch using the micro-simulation model ONCHOSIM, and estimated disability-adjusted life years (DALYs) lost due to onchocerciasis. We assessed financial costs for APOC, beneficiary governments, and non-governmental development organizations, excluding cost of donated drugs. We estimated that between 1995 and 2010, mass treatment with ivermectin averted 8.2 million DALYs due to onchocerciasis in APOC areas, at a nominal cost of about US$257 m

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results